Co-Occurrence of Neurodevelopmental Disorders in Pediatric Sickle Cell Disease.
Co-Occurrence of Neurodevelopmental Disorders in Pediatric Sickle Cell Disease.
复制标题
DOI：
10.1097/dbp.0000000000000914
复制
发表时间：
2021-08-01
期刊：
影响因子：
--
通讯作者：
Casella JF
中科院分区：
文献类型：
--
作者：
Lance EI;Cannon AD;Shapiro BK;Lee LC;Johnston MV;Casella JF
本研究的目的是回顾性确定儿童镰状细胞病临床人群中神经发育障碍的共同发生率、相关特征和风险因素。我们通过2017年7月至2019年1月进行的回顾性队列研究，调查了儿童镰状细胞病中神经发育障碍的共同发生率和特征。参与者是从我们机构的诊所名册和医疗记录数据库中确定的18岁以下镰状细胞病患者。共有276名参与者有资格入选研究，65名参与者被发现患有各种神经发育障碍。与无神经发育障碍的镰状细胞病儿童相比，患有镰状细胞病和神经发育障碍的儿童更可能有多种镰状细胞病相关并发症的病史。与无神经发育障碍的镰状细胞病儿童相比，患有镰状细胞病和神经发育障碍的儿童更可能使用疾病改善疗法（卡方检验227.2，p<0.001）。患有镰状细胞病和神经发育障碍的儿童与没有神经发育障碍的镰状细胞病儿童相比，患有某些疾病相关并发症的几率更高，并且使用疾病改善治疗的几率更高。神经发育障碍的筛查和诊断可能与儿童镰状细胞病的临床管理有关。
The objective of this study is to retrospectively determine the co-occurrence, associated characteristics, and risk factors for neurodevelopmental disorders in a pediatric sickle cell disease clinic population. We investigated the co-occurrence and features of neurodevelopmental disorders in pediatric sickle cell disease through a retrospective cohort study conducted between July 2017 and January 2019. The participants were patients with sickle cell disease under 18 years of age identified from our institutions’ clinic rosters and medical records databases. A total of 276 participants were eligible for study inclusion and 65 participants were found to have various neurodevelopmental disorders. Children with sickle cell disease and neurodevelopmental disorders were more likely to have a history of multiple sickle cell disease-related complications in comparison to children with sickle cell disease without neurodevelopmental disorders. Children with sickle cell disease and neurodevelopmental disorders were more likely to use disease-modifying therapies in comparison to children with sickle cell disease without neurodevelopmental disorders (chi2 27.2, p<0.001). Children with sickle cell disease and neurodevelopmental disorders have higher odds of having certain disease-related complications and higher use of disease modifying treatments than children with sickle cell disease who do not have neurodevelopmental disorders. Screening and diagnoses of neurodevelopmental disorders may be relevant to clinical management of pediatric sickle cell disease.